Clinical Trial Update: Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the use of geriatric assessment to optimize dosing of CDK4/6 inhibitors in older patients with metastatic or advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)
• KISQALI (ribociclib)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Region Örebro County | Conditions: Metastatic Breast Cancer, Advanced Breast Cancer | Phase 3 | Status: RECRUITING